Faculty Presenters

Robert Mancini, PharmD, BCOP

Oncology Pharmacy Program Coordinator
St. Luke's Cancert Institute
Boise, ID

Robert Mancini, PharmD, BCOP, FHOPA is the Oncology/Pharmacy Program Coordinator at St. Luke's Cancer Institute (SLCI) in Boise, ID. Robert started his career working in the realm of oral chemotherapy where he helped start the SLCI Oral Chemotherapy Program about 15 years ago. He went on to serve in multiple additional roles within the Cancer Institute, serving as the pharmacist-in-charge at the Fruitland chemo infusion center, as an oncology supportive care pharmacist as part of an NCCCP grant through the Cancer Institute, helping establish the supportive care clinic model.
 
In 2017, he transitioned to become the first BMT pharmacist and Program Coordinator within the Cancer Institute where he helped establish the allogeneic stem cell transplant program, which is the first and only program in the state of Idaho. In 2022, he went on to also help establish the first and only CAR-T program in the state of Idaho. Since then, he has expanded to assist with program development for specialty areas such as Precision Medicine, Cardio-Oncology, and Supportive Care pharmacist roles. He helped establish the SLCI OP bispecific T-cell engager program as well.
 
He has also served as the PGY2 Oncology Residency Program Director since 2012, having overseen the development of more than 30 PGY2 Oncology Residents. Since 2016, Robert has also served as an adjunct clinical instructor overseeing the oncology therapeutics module at Idaho State University, including starting a special topics oncology elective in 2018. Robert earned his PharmD from the University of California San Diego and completed a PGY1 Hospital Pharmacy Residency at St. Luke's Health System and a PGY2 at St. Luke's Mountain States Tumor Institute (now referred to as SLCI). He has been board certified in oncology since 2012. His research interests include BMT, cellular therapies, and oncology pharmacy education.

Mary Steinbach, DNP, APRN

Lead Advance Practice Clinician
Division of Hematology
University of Utah-Huntsman Cancer Institute
Salt Lake City, UT

Mary Steinbach has been a nurse practitioner in the Division of Hematology and Hematologic Malignancies at the University of Utah's Huntsman Cancer Institute since 2012. Her clinical interests focus on providing evidence-based care for patients with multiple myeloma. Mary's research interests include addressing barriers to accessing cancer care. Through her work, Mary seeks to build a bridge between clinical care and research, striving to enhance outcomes and the everyday experiences of patients living with cancer.

Douglas W. Sborov, MD

Associate Professor
Huntsman Cancer Insitute at University of Utah
Salt Lake City, UT

Dr. Douglas Sborov is an Associate Professor of Medicine and an Adjunct Associate Professor of Molecular Pharmaceutics at the University of Utah and Huntsman Cancer Institute. He is also the Director of the Huntsman Cancer Institute Hematology Disease Center and Plasma Cell Dyscrasias Program, a Huntsman Translational Scholar, and member of the International Myeloma Working Group.

Leila Khaddour, MD

Hematologist and Medical Oncologist
Saint Alphonosus Cancer Center
Boise, ID

Leila Khaddour, MD is a medical oncologist practicing in Boise area. She grew up in Damascus, Syria and finished my medical education and residency and fellowship training there. Dr. Khaddour moved to the United States in 2014. Detroit was her first home. She completed her fellowship at Henry Ford Hospital and was planning to stay in the Midwest. However, COVID pushed her west and she fell in love with Boise. Leila tries her best to server this community and advocate for better patient care. She loves the mountains and the lakes and all what Idaho has to offer. Hiking with her dog is her favorite thing to do!

Program Planning Committee

Charie Gleason, MSN, NP-BC, AOCNP (Content Co-Chair)

VP and Chief APP Officer, Adjunct Faculty

Nell Hodgson Woodruff School of Nursing

Emory Healthcare

Atlanta, GA

Charise Gleason, MSN, NP-BC, AOCNP®, is the VP and Chief Advanced Practice Officer for Emory Healthcare and adjunct faculty at the Nell Hodgson Woodruff School of Nursing at Emory University. She has been a nurse practitioner in the Multiple Myeloma program at the Winship Cancer Institute of Emory University for over twenty years. She earned both her bachelor’s and master’s degrees from Emory University and holds an advanced oncology certification through the ONCC. Ms. Gleason has been an active presenter and educator on the topics of multiple myeloma and has authored or co-authored many publications, including book chapters, abstracts, articles for nursing journals, and scientific publications.

Jesus G. Berdeja, M.D. (Content Co-Chair)

Director of Multiple Myeloma Research

The Greco-Hainsworth Tennessee Oncology Centers for Research

Nashville, TN

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore.

Dr. Berdeja specializes in clinical hematology, with a focus on multiple myeloma. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group and the Clinical Trials Myeloma Intergroup Committee. An active researcher, Dr. Berdeja has been the principal investigator many funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

Disclosures:

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

Charise Gleason, MSN, NP-C, AOCNP discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Jesús G. Berdeja, M.D. discloses contracted research with 2 Seventy Bio, Abbvie, Amgen, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Sanofi, Takeda, Consulting Fee's with AstraZeneca, BMS, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, Takeda and Speaker's Honoraria with Janssen during the past 24 months.